Reader Training

Reader Training is an educational resource from Telix Pharmaceuticals, makers of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide Injection), designed to improve PSMA-11 PET/CT reader skills and increase confidence in identifying pathology while following guidelines to optimize PET/CT reading. Learning modules will include, learning objectives, case study reviews and teaching points presented with video, slides, supporting resources and clinical articles.

Reader Training - Modules 1, 2 and 3
Module 1 - Parts One & Two:
The Basics of 68Ga PSMA-11 PET/CT
Presented by: Nat Lenzo, MD
Module 2:
Considerations for 68Ga-PSMA-11 PET/CT Imaging Interpretation
Presented by: Jaideep S. Sohi, MD
Module 3 - Parts One, Two & Three:
Advanced Reading Skills: A Comprehensive PSMA-11 PET/CT Case Study Review
Presented by: Stefano Fanti, MD and Andrea Farolfi, MD
Featured Program

Clinical Utility of PSMA PET/CT in Prostate Imaging

Insights into the Urology/Oncology Perspective

Presented by: Sanoj Punnen, MD, MAS  |  Preston C. Sprenkle, MD
Scott T. Tagawa, MD, MS, FACP  |  Clint D. Bahler, MD, MS
Prostate Cancer Training

This program is designed to enlighten the Prostate cancer care team about the importance of PSMA Imaging and its impact on patient management and care. This multidisciplinary panel discussion provides clinical perspectives on the utility and the implications of using PSMA PET/CT as a theranostic approach and identifies best practices through the shared clinical experiences of Urologists and Medical Oncologists.

Featured Case Study
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
R. Jeffrey Karnes, MD, FACS   |  Mohamed E Ahmed, MBBCh
Combination Therapy Improves Efficacy in Widespread Prostate Metastatic Disease

A 69-year-old man presented with a persistent rising prostate specific antigen (PSA) of 15.8 ng/mL in September 2019. The patient’s previous PSA readings were 11.4 ng/mL in November 2018 and 12.9 ng/mL in May 2019.

The patient had a known history of prostate cancer and was treated initially with Radical Retropubic Prostatectomy (RRP) for Gleason 3 + 4 = 7. The patient subsequently experienced biochemical recurrences and was treated with salvage external beam radiation therapy, intermittent hormone therapy with leuprolide, and 3 cycles of Provenge.